VEGFB and diabetes mellitus: For example, here we reported that the compound heterozygous carrier of both c.322A ​> ​C; p.S108R in VEGFB and c.502+1G ​> ​A in ITGA2 had more severe clinical symptoms and serum DM levels; thus, more attention should be exerted towards such population.